Covidien Hernia Mesh Lawsuit
(Parietex, ProGrip & Symbotex Mesh)
Federal litigation alleging Covidien's polyester hernia mesh products, including Parietex Composite, ProGrip self-gripping mesh, and Symbotex Composite, caused serious complications including chronic pain, mesh migration, adhesions, infections, and hernia recurrence requiring additional surgeries. On August 4, 2026, the first federal bellwether trial ended in an $88 million jury verdict against Covidien.
$88 Million Verdict in the First Federal Bellwether Trial
On August 4, 2026, a federal jury in the District of Massachusetts returned an $88 million compensatory verdict against Covidien in Patterson v. Covidien, the first case from MDL-3029 to reach trial. The jury awarded $77 million to Larry Patterson and $11 million to Tammy Patterson on her loss-of-consortium claim. Jurors found that Covidien failed to adequately warn physicians about the risks of its Symbotex Composite mesh, but declined to award punitive damages and rejected the claim that the company acted intentionally or recklessly in making false statements.
Medtronic, which acquired Covidien in 2015, has stated that it disagrees with the verdict and intends to pursue post-trial motions and, if necessary, an appeal.
What this does and does not mean. This was a jury verdict, not a settlement. Some published summaries have described it as a settlement; that is inaccurate. A verdict is not final while post-trial motions and appeals are pending, and the amount may be reduced or set aside. A bellwether outcome is intended to help both sides evaluate the strength of similar claims. It does not establish a payment amount for any other case, and it does not mean other claimants will receive compensation.
Key Takeaways
- $88 million verdict in the first federal bellwether trial (August 4, 2026). This is a verdict, not a settlement, and it remains subject to post-trial motions and appeal
- Over 2,400 cases pending as of August 2026 with 51% growth
- Medtronic acquired Covidien for $49.9 billion in 2015
- 2023: Class 2 FDA recall for defective collagen film placement
- Polyester mesh products include Parietex Composite and ProGrip
- Allegations include chronic pain, adhesions, infections, and hernia recurrence
Key Facts (August 2026)
| Pending Actions | 2,449+ cases in federal MDL |
| Total Actions Filed | 2,455+ cases |
| First Bellwether Trial | Patterson v. Covidien: $88 million jury verdict, August 4, 2026 (post-trial motions and appeal expected) |
| Global Settlement | None. No global settlement has been announced in MDL-3029. |
| Key Defendants | Covidien LP, Medtronic plc, Sofradim Production SAS |
| Presiding Judge | Hon. Patti B. Saris (D. Massachusetts) |
| MDL Created | June 6, 2022 (transferred by JPML) |
| Mesh Material | Polyester with absorbable collagen coating |
| 2023 FDA Recall | Class 2 recall for defective collagen film placement |
| Can You Still File? | Yes, lawsuits are actively being filed |
Rapid Case Growth
Cases against Medtronic/Covidien continue to surge. Case count has grown 51% since January 2025 as mesh complications emerge.
Source: JPML MDL Statistics Reports, January 2025-August 2026
FDA Class 2 Recall (January 2023)
The FDA issued a Class 2 recall (Z-1183-2023) for Parietex Composite Mesh after discovering the collagen film was placed on the opposite side of the mesh. This manufacturing defect can cause:
Source: FDA Medical Device Recalls Database, Recall Number Z-1183-2023
1 What Is This Lawsuit About?
According to the FDA, a hernia occurs when an organ, intestine, or fatty tissue squeezes through a hole or weak spot in the surrounding muscle or connective tissue. Approximately one million hernia repairs are performed in the United States each year, with the vast majority using surgical mesh.
This MDL consolidates cases against Covidien (now owned by Medtronic) and its French manufacturer Sofradim Production SAS. Plaintiffs allege that Covidien's Parietex polyester mesh products caused serious complications that were not adequately disclosed.
2 Products Involved in Litigation
Sofradim Production (Covidien's manufacturer) has received 18 FDA 510(k) clearances for Parietex-branded products from 1999 to 2022. Key products include:
Parietex Composite (PCO) Mesh
- • Polyester mesh with absorbable collagen/hydrogel barrier coating
- • Designed for intraperitoneal placement (directly against abdominal organs)
- • First FDA cleared: February 15, 2001 (K002699)
Parietex ProGrip Self-Gripping Mesh
- • Self-fixating mesh with micro-grips made of polylactic acid (PLA)
- • Designed to eliminate need for sutures or tacks during implantation
- • First FDA cleared: May 28, 2008 (K081050)
Symbotex Composite Mesh
- • Polyester mesh with absorbable collagen barrier
- • 3D design features for anatomical fit
- • FDA cleared: November 14, 2014 (K142908)
3 Alleged Injuries & Complications
The FDA MAUDE database shows 345+ adverse event reports for Parietex products in 2025 alone. Plaintiffs allege these complications:
Mesh Failure
- Mesh shrinkage and contraction
- Migration from original implant site
- Hernia recurrence
- Impaired healing
Infection & Inflammation
- Chronic infection at implant site
- Abscess formation
- Seroma (fluid buildup)
- Fibrosis (scarring)
Organ & Tissue Damage
- Adhesions to bowel and organs
- Bowel obstruction
- Fistula formation
- Organ perforation
Pain & Additional Surgery
- Chronic abdominal pain
- Revision surgery to remove mesh
- Multiple corrective procedures
- Prolonged antibiotic treatment
4 FDA Regulatory Background
Hernia mesh devices are regulated by the FDA as Class II medical devices through the 510(k) clearance pathway. Unlike Class III devices that require clinical trials (PMA), 510(k) clearance only requires demonstrating that a new device is "substantially equivalent" to a device already on the market.
Key Distinction:
According to the FDA, potential risks of mesh-reinforced hernia repair include pain, infection, hernia recurrence, adhesion, obstruction, bleeding, fistula, seroma, perforation, and mesh migration or shrinkage.
5 MDL Timeline & Status
Defendants moved to consolidate 73 initial actions from multiple federal districts including Florida, New Jersey, Louisiana, Missouri, and Oklahoma.
The Judicial Panel on Multidistrict Litigation transferred cases to the District of Massachusetts before Judge Patti B. Saris.
Covidien LP initiated a recall of Parietex Composite Mesh due to defective collagen film placement affecting 53 units distributed globally.
Court-ordered mediation, with a deadline extended into early 2026, ended without a global settlement. Judge Saris denied Covidien's motion for summary judgment in the lead bellwether case, clearing the way for the MDL's first trial.
Patterson v. Covidien, a Symbotex Composite mesh case, went before a jury in the District of Massachusetts. The plaintiff alleged that the mesh's absorbable collagen barrier resorbed far faster than represented, allowing the mesh to adhere to bowel tissue and requiring a second surgery to remove the device and a section of intestine.
After a roughly three-week trial, the jury returned a compensatory award of $88 million on a failure-to-warn theory, consisting of $77 million to Larry Patterson and $11 million to Tammy Patterson for loss of consortium. The jury declined to award punitive damages and rejected the allegation that Covidien acted intentionally or recklessly in making false statements. Medtronic has said it disagrees with the verdict and will pursue post-trial motions and an appeal, so the award is not final. MDL-3029 continues with 2,449+ pending federal actions, plus thousands of additional claims in Massachusetts and Minnesota state courts. No global settlement has been announced.
6 Who May Qualify for a Lawsuit?
Eligibility Requirements
- Had hernia repair surgery using Covidien/Parietex mesh (Parietex Composite, ProGrip, or Symbotex)
- Experienced complications such as pain, infection, mesh migration, adhesions, hernia recurrence, or organ damage
- Required additional surgery or medical treatment due to mesh-related problems
- Have medical records documenting the mesh implant and subsequent complications
7 Defendants in This Litigation
Covidien Entities
- • Covidien LP
- • Covidien Holding Inc.
- • Covidien, Inc.
- • Covidien plc
- • Covidien Sales LLC
Related Companies
- • Medtronic plc (acquired Covidien 2015)
- • Medtronic, Inc.
- • Medtronic USA, Inc.
- • Sofradim Production SAS (manufacturer)
- • Tyco Healthcare Group
Frequently Asked Questions
How is Covidien mesh different from Bard mesh?
Covidien's Parietex products use polyester mesh with absorbable collagen barriers, while Bard products primarily use polypropylene. Both materials have been linked to similar complications including migration, adhesions, and chronic pain, but they involve different chemical compositions and may cause different types of tissue reactions.
How do I know if I have Covidien mesh?
Your surgical records and operative report should identify the specific mesh product used. Look for product names like "Parietex," "ProGrip," or "Symbotex." You can also request your medical records from the hospital or surgery center where your procedure was performed. An attorney can help you obtain these records.
What compensation might I receive?
Compensation in hernia mesh cases may include medical expenses (past and future), lost wages, pain and suffering, and diminished quality of life. The amount depends on factors like severity of complications, number of revision surgeries, permanent injuries, and impact on daily activities. An attorney can evaluate your specific situation.
Does it cost anything to file a lawsuit?
Most hernia mesh attorneys work on a contingency fee basis, meaning they only get paid if you win or settle your case. The fee is typically a percentage of the recovery. Initial consultations are usually free, allowing you to understand your options without any upfront cost.
Sources & References
11 official sources cited• FDA, "Surgical Mesh Used for Hernia Repair" (fda.gov/medical-devices/implants-and-prosthetics/surgical-mesh-used-hernia-repair)
• FDA 510(k) Premarket Notification Database
• FDA MAUDE (Manufacturer and User Facility Device Experience) Database
• FDA Medical Device Recalls Database, Recall Z-1183-2023
• JPML MDL Statistics Report, Pending MDL Dockets by Actions Pending, August 1, 2026
• U.S. District Court for the District of Massachusetts, In re: Covidien Hernia Mesh Products Liability Litigation (No. II), MDL No. 3029 (Hon. Patti B. Saris)
• SEC EDGAR Company Filings (Covidien and Medtronic entities)
• PubMed: Molegraaf MJ, et al. Ann Surg. 2017;266(6):939-945 (PMID: 28257318)
• Reuters, reporting on the Patterson v. Covidien bellwether verdict (August 4-5, 2026)
• MassDevice, "Jury says Medtronic must pay $88M in Covidien hernia mesh suit" (August 5, 2026)
• Star Tribune, "Bellwether hernia case ends in $88M verdict against Medtronic" (August 2026)
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.